Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation

Cell Cycle

Volumn 8, Issue 9, 2009, Pages 1373-1379

  Fernandez Vidal, Anne ^a   Mazars, Anne ^a   Gautier, Emilie Fleur ^a   Prévost, Grégoire ^b   Payrastre, Bernard ^a,c   Manenti, Stéphane ^a,d  

^a University of Toulouse III   (France)

^b Institut Henri Beaufour   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d CHU PURPAN   (France)

Author keywords

CDC25A; Lymphoma; Oncogene; PI3K; Proliferation; Tyrosine kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACTIVIN; ACTIVIN RECEPTOR LIKE KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; HEMATOPOIETIC CELL KINASE; IMATINIB; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RMIL-3; RNA; UNCLASSIFIED DRUG; WHI-154; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG TARGETING; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEMATOLOGY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 65949109269     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.9.8302     Document Type: Article

References (26)

1. + anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96:3681-3695
2. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281-1284
3. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumours. Blood 2003; 101:1919-1927.
4. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, et al. Ablation of oncogenic ALK is a viable approach for anaplastic large-cell lymphomas. Blood 2006; 107:689-697
5. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the Phosphatidyl-inositol 3-kinase/Akt antiapoptotic signalling pathway. Blood 2000; 96:4319-4327
6. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidyl-inositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61:2194-2199
7. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM-ALK induces activation of the MEK/ERK signalling pathway independently of c-raf. Oncogene 2007; 26:813-821 (Pubitemid 46245735)
8. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, et al. Nucleophosminanaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60src to mediate its mitogenicity. Blood 2004; 103:1464-1471
9. Chiarle R, Simmons W, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11:623-629
10. 1 cell cycle arrest in ALK positive anaplastic large cell lymphoma. Oncogene 2004 ; 23:5426-5434
11. Kip1 in a PI-3K-dependent manner. Exp Hematol 2004; 32:1265-1271
12. Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005; 105:827-839
13. - anaplastic large cell lymphoma. Hum Path 2005; 36:806-811
14. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:1-12.
15. Chen X, Prywes R. Serum-induced expression of the CDC25A gene by relief of E2F-mediated repression. Mol Cell Biol 1999; 19:4695-4702 (Pubitemid 29289507)
16. Galaktionov K, Chen X, Beach D. CDC25A cell cycle phosphatase as a target of c-myc. Nature 1996; 382:511-517 (Pubitemid 26260686)
17. 1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000; 20:3497-3509
18. Barre B, Vigneron A, Coqueret O. The STAT3 transcription factor is a target for the Myc and retinoblastoma proteins on the CDC25A promoter. J Biol Chem 2005; 280:15673-15681 (Pubitemid 40616686)
19. 1/S cell cycle phosphatase Cdc25A. Oncogene 2007; 26:1949-1953.
20. Busino L, Chiesa M, Draetta G, Donzelli M. CDC25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004; 23:2050-2056 (Pubitemid 38496734)
21. Löffler H, Syljuasen RG, Bartkova J, Worm J, Lukas J, Bartek J. Distinct mode of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 2003; 22:8063-8071 (Pubitemid 37487297)
22. Ray D, Terao Y, Fuhrken P, Ma ZQ, DeMayo FJ, Christov K, et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 2007a; 67:984-991
23. Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, Zou X, et al. Hemizygous disruption of cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 2007b; 67:6605-6611
24. Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer 2009; 124:1449-1456
25. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, et al. GSK-3beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008 ;13:36-47.
26. Fernandez-Vidal A, Ysebaert L, Didier C, Betous R, De Toni F, Prade-Houdellier N, et al. Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res 2006; 66:7128-7135